I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Nicolas Barthelemy net worth and biography

Nicolas Barthelemy Biography and Net Worth

Director of Repligen

Nicolas Barthelemy has served as a member of our board of directors since March 2017. Mr. Barthelemy brings over 29 years of health care industry experience to the Fluidigm Board, having served in multiple senior executive roles in the biopharmaceutical, life science tools, and molecular diagnostics sectors. He previously served as President and CEO of Biotheranostics, a privately held molecular diagnostics company, from 2014 until February 2017. Just prior to that, he served as President of Global Commercial Operations at Life Technologies, a $4 billion life science industry leader that was acquired by Thermo Fisher Scientific in 2014. Prior to that position, he led the $850 million Cell Systems Division for five years at Life Technologies. Before Life Technologies, Mr. Barthelemy was with Biogen for eight years in operational and commercial roles of increasing responsibility, including Vice President of Manufacturing. He began his career with Merck & Co., Inc. as a Project Engineer in the Vaccine Division. Mr. Barthelemy currently also serves on the boards of directors of Repligen Corporation and Twist Bioscience Corporation. He received an M.S. in chemical engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et de Chimie Industrielles in Paris.

What is Nicolas Barthelemy's net worth?: The estimated net worth of Nicolas Barthelemy is at least $1.94 million as of May 11th, 2022. Mr. Barthelemy owns 13,939 shares of Repligen stock worth more than $1,936,127 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Barthelemy may own. Learn More about Nicolas Barthelemy's net worth.
How do I contact Nicolas Barthelemy?: The corporate mailing address for Mr. Barthelemy and other Repligen executives is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. Repligen can also be reached via phone at (781) 250-0111 and via email at [email protected]. Learn More on Nicolas Barthelemy's contact information.
Has Nicolas Barthelemy been buying or selling shares of Repligen?: Nicolas Barthelemy has not been actively trading shares of Repligen in the last ninety days. Most recently, Nicolas Barthelemy sold 1,645 shares of the business's stock in a transaction on Friday, October 29th. The shares were sold at an average price of $288.20, for a transaction totalling $474,089.00. Learn More on Nicolas Barthelemy's trading history.
Who are Repligen's active insiders?: Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Christine Gebski (Insider), Anthony Hunt (Executive Chair), Ralf Kuriyel (VP), Martin Madaus (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.
Are insiders buying or selling shares of Repligen?: In the last year, Repligen insiders bought shares 2 times. They purchased a total of 3,615 shares worth more than $449,938.10. In the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 72,325 shares worth more than $12,382,469.27. The most recent insider tranaction occured on September, 10th when Director Anthony Hunt sold 22,191 shares worth more than $3,225,905.67. Insiders at Repligen own 1.2% of the company. Learn More about insider trades at Repligen.
Information on this page was last updated on 9/10/2024.

Nicolas Barthelemy Insider Trading History at Repligen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/29/2021	Sell	1,645	$288.20	$474,089.00
11/9/2020	Sell	1,214	$195.51	$237,349.14	1,450
4/22/2020	Sell	2,688	$109.99	$295,653.12	5,725
4/3/2020	Sell	2,688	$99.99	$268,773.12	6,761
8/29/2018	Sell	6,580	$54.44	$358,215.20	8,774
5/9/2018	Sell	26,500	$40.54	$1,074,310.00	27,988

Nicolas Barthelemy Buying and Selling Activity at Repligen

Repligen Company Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $140.13

$136.59

$140.85

50 Day Range

MA: $140.21

$123.41

$150.47

2 Week Range

Now: $140.13

$113.50

$211.13

Volume

178,016 shs

Average Volume

667,805 shs

Market Capitalization

$7.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.